A blockbuster Amgen drug for osteoporosis now carries the FDA’s strictest warning that its use can lead to dangerously low levels of calcium in the blood. This complication, hypocalcemia, is a ...

Prolia is a monoclonal antibody that binds to a specific protein on osteoclasts and decreases their activity. Osteoclasts are responsible for dissolving and breaking down old or damaged bone cells. By ...

Prolia (denosumab) is a prescription drug used to treat osteoporosis and strengthen bones in certain people. This drug can interact with some other medications. For example, Prolia can interact with ...

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

The U.S. Food and Drug Administration (FDA) has issued a black box warning — reserved for the most serious safety issues — for the osteoporosis drug denosumab, sold under the brand name Prolia.

According to a long-term safety study and a separate FDA internal study, Prolia had an increased risk of hypocalcemia in patients with advanced kidney disease on dialysis. Patients with advanced ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...

Original Medicare (Part A and Part B), Part D, and Medicare Advantage typically offer coverage for the osteoporosis drug Prolia. However, individuals must meet certain requirements for Part B coverage ...

[email protected]. Question: My new doctor says that my Prolia shot will be very expensive. When my previous physician gave me the shot it was covered in full. Why the difference in cost?

Teva shared that the Food and Drug Administration has accepted, and the European Medicines Agency has validated, applications for TVB-009P, a biosimilar candidate to Amgen’s Prolia (denosumab). Both ...